Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-OPS202 PET Uptake Time in Breast Cancer
NCT03697551Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Alpha Emitters, Beta Emitters, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of satoreotide in breast cancer, sponsored by Ipsen. Primary endpoints: Percentage of Subjects With Sufficiently Avid Lesion(s) Identified as a sstr2 Positive Lesion at 2.0 hours and Differences in the Number of Lesions Detected by 68Ga-Satoreotide Trizoxetan Between the 3 PET Acquisition Timepoints in Primary Breast Lesions at 2.0 hours. Started Oct 2018; status: terminated.
02
Drugs
satoreotide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03697551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697551.